Displaying 1-10 letters out of 521 published
Thiamine compounds in humans
I have some comments concerning the report by S. Jesse, D.R. Thal and A.C. Ludolph, recently published in JNNP September 15 2015, pag. 1166-1168 "Thiamine deficiency in Amyotrophic Lateral Sclerosis". In a research dated 1981 Rindi et al. showed that in 12 CSF samples obtained from different healthy subjects, without any clinical disorder involving thiamin status, the only thiamin compounds detected after electrophoretic separation were constantly free thiamine (T) and thiamine- monophosphate (TMP), their mean percentage being 40.7% and 59.3% of total thiamin content respectively. EXPERIENTIA 37, 975-976 (1981). In a successive study Poloni et al. (Arch. Neurol., 1982,39, 507-509) measured free thiamin and thiamin monophosphate levels in plasma and cerebral spinal fluid of patients with ALS, alcoholics, and controls. In plasma of patients with ALS, as well as in plasma and cerebrospinal fluid (CSF) of alcoholics, both thiamin and thiamin monophosphate concentrations were decreased. In CSF of patients with ALS, however, thiamin monophosphate values decreased much more than thiamin levels. This same finding has been observed, interestingly, only in pigs who showed together with rabbits, the highest levels of thiamine in the CSF. In our opinion the selective impairment of thiamin monophosphate production by nerve cells is likely to result from the reduction of the activity of thiamin pyrophosphatase, an enzyme synthesized and highly concentrated in the Golgi complex, a component of the cell where complex molecules such as proteins are synthesized and packaged for use in the body. Thiamin pyrophosphatase diminish in ALS, as well as in experimental motor neuronal degeneration or axotomy. Thus, the thiamin to thiamin monophosphate ratio could be taken as an index of the impairment of neuronal protein synthesis in ALS (Poloni et al.., Arch. Neurol., 1982, 39, 507-509). In an other study, thiamine and thiamine monophosphate levels were measured in the CSF of patients with typical sporadic ALS (50 cases), in other motor neuron diseases (MND) (14 cases), and in patients with upper and/or lower motor neuron lesions of varying origin (disseminated sclerosis, polyneuropathy, spondylotic myelopathy). The thiamine to thiamine monophosphate ratio was greater than or equal to 1 in a high percentage of patients with typical sporadic ALS (94%), in 35.7% of cases with other MND, while it was below one in all the other patients. The decrease of thiamin monophosphate with the inversion of the thiamin to thiamin monophosphate ratio is a finding highly specific to typical sporadic ALS (Poloni et al. It.J.Neurol: Sci.,1986). Other researchers measured the enzymes involved in thiamin synthesis: thiamin pyrophosphatase (TPPase) and thiamin monophosphatase (TMPase) in brain tissue obtained at autopsy from ALS and Parkinsonism-dementia patients from Guam and from Guamanian patients who died from other diseases (controls). TPPase content, chemically determined at pH 9.0, was found to be significantly reduced in the frontal cortex of ALS and Parkinsonism-dementia patients compared to controls. TMPase content, on the contrary, was unchanged (Laforenza et al., J. Neurol. Sci., 1992). Thiamin deficiency causes dry beriberi, a neurologic al disease characterized by "burning" feet, peripheral neuropathy, and Wernicke- Korsakoff syndrome; on this background, in my opinion the method used in this paper to determinate the level of thiamine is indirect and easily subject to drawbacks; Wernicke encephalopathy, istologically observed in two ALS cases, may be due to undernutrition that may be frequently associated in a disease where severe dysphagia may be present in the terminal stage. The reason of the low TMP CSF levels with inversion of the ratio T/TMP, peculiar of ALS patients and ineterestingly found only in pigs, remains unexplained.
Conflict of Interest:
Cholinesterase inhibitors and falls in Parkinson's disease
We read with great interest the paper by Pagano et al. who conducted a systematic review of prospective, randomised placebo-controlled trials (RCT), in order to assess the efficacy and safety of cholinesterase inhibitors (ChIs) in patients with Parkinson's disease (PD). They concluded that ChIs are effective in the treatment of cognitive impairment in patients with PD. We concur with the authors' nuanced conclusion in the Discussion that based on this meta-analysis no exclusive position can be assumed regarding the efficacy of ChIs in the treatment of frequent falling in PD patients. As the authors point out, the included RCT study by Chung et al. showed that ChI (donepezil) treatment was most effective in the subgroup of patients with frequent falls. This observation suggests that a possible therapeutic indication for cholinergic augmentation therapy to treat falls in PD may require a more personalised or precision type of medicine approach. Cholinergic treatment for falling will most likely have highest efficacy in those PD patients that have the most profound cholinergic system loss, i.e. frequent falling with comorbid cognitive impairment. This may be readily identified by a simple clinical routine, however, this approach would need further validation. It should be noted that cognitive impairment and frequent falling in PD may be caused not only by cholinergic system loss. We have recently shown that cognitive impairment, freezing of gait, and other axial motor impairments are also associated with the presence of beta-amyloid proteinopathy in PD.[4-6] Therefore, future studies should not only have a more detailed fall status assessment but also identify other extra-nigral pathologies in PD that may preclude optimal cholinergic augmentation therapy in these patients.
1. Pagano G, Rengo G, Pasqualetti G, et al. Cholinesterase inhibitors for Parkinson's disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2015;86:767-73.
2. Chung KA, Lobb BM, Nutt JG, et al. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 2010;75:1263-9.
3. Muller ML, Bohnen NI, Kotagal V, et al. Clinical markers for identifying cholinergic deficits in Parkinson's disease. Mov Disord 2015;30:269-73.
4. Petrou M, Bohnen NI, Muller ML, et al. Abeta-amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology 2012;79:1161-7.
5. Muller ML, Frey KA, Petrou M, et al. Beta-amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia. Mov Disord 2013;28:296-301.
6. Bohnen NI, Frey KA, Studenski S, et al. Extra-nigral pathological conditions are common in Parkinson's disease with freezing of gait: an in vivo positron emission tomography study. Mov Disord 2014;29:1118-24.
Conflict of Interest:
Comments on "Meta-analysis of modifiable risk factors for Alzheimer's disease"
The meta-analysis by Xu et al., (2015) reviews over 300 papers and identified 93 modifiable risk factors for Alzheimer's disease. Among these risk factors, population attributable risks (PAR) of nine important factors were estimated to contribute to up to 66% of Alzheimer's disease cases globally. We acknowledge the great effort of this massive review but there are some substantial analytical issues which should be highlighted.
(1) Mixture of odds ratio (OR) and relative risk (RR) in the review Although the authors clearly knew the difference between odds ratio (OR) and relative risk (RR) they still combined these results and generated pooled estimates in the meta-analysis. It is generally considered problematic to combine these two epidemiological measures. Odds ratios tend to provide a stronger effect size than relative risks with the two measures only being very close if the prevalence of a disease/disorder is very low. Dementia and Alzheimer's disease are not rare therefore this approach may have led to overestimation of the effect size of risk factors. Although the authors stratified cohort and case-control studies in the meta-analyses, they still reported overall pooled estimates. Given the large number of papers, it would have been possible to focusing only on studies reporting relative risk.
(2) Grades of evidence Grades of evidence were based on heterogeneity and pooled population size. Although heterogeneity indicates consistency of the results across individual studies, a non-significant I-squared should not be taken as evidence of no heterogeneity. In particular, observational studies generally depend on their research settings and use a variety of methods with diverse study populations. Apparently, similar results can mask considerable underlying variation.
In the appendix, the authors further excluded some studies according to concerns about study quality and methods. This is an important methodological point and exclusion of studies requires a systematic approach in order for the reader to understand the decisions reviewers have made. Assessments of study quality should be included in "grades of evidence". This corresponds to the first point that the authors could have focused on studies using prospective designs and proper methodologies to provide robust estimates.
(3) PAR estimation without taking inter-relationship of risk factors into account The PAR calculation did not take into account the inter-relationship between the nine factors leading to spuriously high PAR estimates (66%). Other studies[4,5] have addressed this recognised limitation and an updated analysis of the paper cited by Xu et al was published precisely to correct this important concern. This reduces PAR to around 30%. This is because risk factors such as obesity/low BMI index, frailty/low BMI index (and indeed education and depression) are known to be highly related. Epidemiologists are well aware of the joke that with such naive analyses we claim to be able to prevent over 100% of disorders.
Finally, some confusing factors such as "current smoking in Asian population" and "diabetes mellitus-II in Asian population" were included in the analysis. The authors suggest the PAR estimate was applied to global Alzheimer's disease cases, but these factors only focus on Asian populations. It is unclear whether it is appropriate to apply these globally.
We suggest that the findings of this paper over-estimate the effect size and contribution of risk factors for dementia and Alzheimer's disease and that, unfortunately, this contributes to further confusion in wildly over-interpreted media headlines.
 Xu W, Tan L, Wang H-F, Jiang T, Tan M-S, Tan L, et al. Meta- analysis of modifiable risk factors for Alzheimer's disease. Journal of Neurology, Neurosurgery & Psychiatry. 2015. DOI: 10.1136/jnnp-2015- 310548
 Bonita R, Beaglehole R & Kjellstrom T. WHO Basic Epidemiology. 2006. Available: apps.who.int/iris/bitstream/10665/43541/1/9241547073_eng.pdf
 Higgins J & Green S. Cochrane Handbook for Systematic Reviews of Interventions. 2011. Available: handbook.cochrane.org/chapter_9/9_5_2_identifying_and_measuring_heterogeneity.htm
 Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer's disease: an analysis of population- based data. The Lancet Neurology. 2014;13(8):788-94.
 Di Marco LY, Marzo A, Mu?oz-Ruiz M, Ikram MA, Kivipelto M, Ruefenacht D, et al. Modifiable lifestyle factors in dementia: a systematic review of longitudinal observational cohort studies. Journal of Alzheimer's Disease. 2014;42(1):119-35.
 Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. The Lancet Neurology. 2011;10(9):819- 28.
Conflict of Interest:
Treatment of neuropsychiatric syndromes in Alzheimer's disease (AD): In search of evidence?
We read with interest the recent systematic review and meta-analysis, "Pharmacological treat-ment of neuropsychiatric symptoms in Alzheimer's disease"(1). By examining the evidence for treating heterogeneous range of neuropsychiatric syndromes in persons with Alzheimer's disease (AD), this study found favorable results for the use of cholinesterase inhibitors (ChEIs) and atyp-ical antipsychotics albeit with risk of side effects, but not for selective serotonin uptake inhibitors (SSRIs), mood stabilizers, or an N-Methyl-D-Aspartate receptor antagonist. The authors sug-gested that their result is generalizable across the spectrum of AD severity. While these findings are important, the results could be expanded. For example, important points including investiga-tion of the heterogeneity (in assessment scales, results, and severity of AD), and methodological limitations need addressing for better understanding of the relative significance of the findings. The Neuropsychiatric Inventory (NPI) used in these trials varies and captures a range of 10 to 12 syndromes. These variations increase the heterogeneity in the findings. Furthermore, this hetero-geneity is enhanced when different compounds with differing mechanism of action or affinity that are designed primarily for individual syndrome use (e.g., antipsychotics for psychosis or de-lusion, or antidepressant for depression, or apathy) are combined. In other words, total NPI score is not necessarily the best reflection of improvement, rather, looking at subtest of items is per-haps more relevant not only in light of studying mechanism of action for each compound, but also for better treatment planning. Same can be said in light of the NPI that aggregates many dif- ferent symptoms, although all related to Behavioral and psychological symptoms of dementia (BPSD), one cannot reasonably expect each medication to be beneficial to all BPSD - i.e. depres-sion and apathy may require something slightly stimulating, while anxiety and agitation may re-quire something slightly sedating. Combining them all under total NPI score and expecting a medication that can cure all is unreasonable. It would have been more informative if these stud-ies reported the effect of each drug on the specific BPSD syndromes and have proper scales to quantify them. Although well formulated to quantify the benefits and safety profiles of various compounds on overall neuropsychiatric syndromes, this meta- analysis could have benefited from taking into account several methodological points, including 1) whether the goal of the included studies was primary or secondary to investigate neuropsychiatric syndromes; and 2) investigated moderating clinical factors.
The first concern of this study is the lack of explicit statement about the goal of the included studies, which could have shown experimenter bias. This is important for two reasons, A) if the primary goal of the studies was other than neuropsychiatric syndrome, the weight given to indi-vidual compounds would be different. For example, one would anticipate that the cholinesterase inhibitor trials would not be primarily set to find differences in behavioral issues versus the atyp-ical antipsychotic trials, which would be particularly designed to identify such an effect. B) This could be a power issue in that, if the secondary data come from post-hoc analysis, the result could have been underpowered. The second concern is the absence of moderating factors such as inpatient/outpatient, treatment duration, dosage, or severity of AD investigation. Teasing-apart treatment effect for mild, moderate, or severe AD would have added more strength to their find-ing. It is possible that the lack of effect observed in some of the studies is masked because of se-verity of AD, or that optimal dosage was not applied for the preferred duration of treatment.
In conclusion, with both favorable and dissenting results, although the meta-analysis is well de-signed and carried out, it could have been more informative about the use of psychotropic medi-cation for treating neuropsychiatric syndromes in AD. It could have informed us about the use of each compound for specific AD severity, and duration and dosage of treatment. Also, it could have added notes as to whether these treatment approaches are optimal when used in combina-tion or alone. Given that this study compares itself to earlier meta-analysis and reviews, thus fu-ture studies further benefit by taking into consideration of the above- mentioned points to opti-mize findings.
1. Wang J, Yu JT, Wang HF, et al. Pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2015;86(1):101-109.
Conflict of Interest:
Hazards of formaldehyde in the workplace.
The article by Roberts and colleagues on formaldehyde and ALS, is important for its contribution to job related hazards of formaldehyde exposure. One occupation that would be interesting to examine, is wood working/carpentry using mainly plywood. At the core of its manufacture, is formaldehyde. Plywood for indoor use generally uses urea-formaldehyde glue, which has limited water resistance, while outdoor and marine-grade plywood are designed to withstand moisture, and use a water resistant phenol-formaldehyde glue.. Working with plywood produces significant amounts of fine dust containing formaldehyde as well as wood particles. If adequate protection is not used, and ventilation poor, the results can range from eye irritation to various forms of respiratory compromise. Neurological effects are equally likely, especially after years of working in similar dust/formaldehyde environments.
Conflict of Interest:
Paralympics and Conversion Disorder - "secondary gain" should not be a reason for exclusion
Anthony David's article on Paralympics and conversion disorder opens an important and useful debate about the legitimacy of physical disability when related to a functional (psychogenic) disorder and the extent to which patients with these disorders should have access to the normal rights of a disabled person(3). If functional disorders, and to be clear we are talking here specifically about functional limb weakness, are a genuine cause of disability why would they be excluded from the paralympics?
The article highlighted the important fact that conversion disorder does not stand alone in being excluded from Paralympic classification and that each sport has different rules(5). The classification itself however is not based on disease categories but on impairments that are quantifiable and permanent. As a result many disabling conditions do not 'fit'. As well as chronic pain and epilepsy, it is important we think to highlight that other 'motor' neurological disorders including Parkinson's disease are usually excluded so this is not an issue about having a pathological disease to get you "entry to the club".
We recognise the need for fairness and agree there is an inherent problem in allowing someone with functional limb weakness that, by definition can transiently improve, in competing against athletes with fixed deficits. Improvement in motor function in functional disorders occurs when the patient is not attending to the limb and is often hard for the person themselves to appreciate(6). Whether this is really an issue in sports where the limb is not ostensibly being used anyway, such as wheelchair sports is debatable, although we recognise there may be advantages in terms of core stability or training for the patient with a functional disorder and matching deficits could be difficult.
However, we don't agree that issues of 'secondary gain' should come in to the discussion. "Secondary gain", the interpersonal or social advantage that occurs secondary to illness which may unconsciously perpetuate disability, is not specific to patients with functional disorder but exists across the whole spectrum of disease. What differs is our social response to it. In many situations we actively encourage it, helping the patient solicit disability benefits or participation in 'positive' disability activities. But for some disorders we actively discourage it believing it is not in the patients best interest to benefit from being unwell- such considerations are almost always made in a paternalistic fashion with little open discussion with patient about what is in their interest. In fact decisions on secondary gain can quickly become moral judgements and are prone to error, prejudice and social bias.
In a hypothetical future in which spinal cord injury could be cured with regenerative medicine, would we ban all patients with potentially curable conditions from taking part to make sure that they were all correctly motivated to treatment? Patients with epilepsy sometimes refuse surgery even when its offered(2) and experience the 'burden of normality' that seizure freedom may bring(7). But we do not ban patients with epilepsy from state related financial benefits if they refuse treatment.
The reality for many patients with functional motor disorders is that their condition may not be reversible even if it retains the potential for improvement. Patients may not even be a candidate for treatment, either because of lack of success of previous treatment or poor availability of adequate treatment. Furthermore, many well motivated patients do not achieve improvement even with access to treatment(4). Is paralympic sport a bad outcome in such circumstances?
Finally we dont agree that the DSM-5 definition of conversion disorder (CD) which includes the criterion that "The symptom or deficit causes significant distress, psychosocial impairment or warrants medical evaluation" implies that 'the person with CD is barred from overcoming or compensating for their predicament, or coping with it positively, e.g. taking up competitive sports), without distress'(1)(3). The criterion is worded with an 'or' to ensure that patients can receive this diagnosis who are coping it with positively but still require medical evaluation to determine why they have a motor symptom.
We can see the difficulties of classifying patients with functional limb weakness for Paralympic sport but do not think issues of secondary gain should be a factor in deciding eligibility.
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5TM). Arlington, Virginia: American Psychiatric Press, Inc.; 2013.
2. Anderson CT, Noble E, Mani R, Lawler K, Pollard JR. Epilepsy Surgery: Factors That Affect Patient Decision-Making in Choosing or Deferring a Procedure. Epilepsy Res Treat 2013; 2013:10.1155/2013/309284.
3. David AS. Paralympics and conversion disorder. J Neurol Neurosurg Psychiatry 2015; :10.1136/jnnp - 2014-309957.
4. Gelauff J, Stone J, Edwards M, Carson A. The prognosis of functional (psychogenic) motor symptoms: a systematic review. J Neurol Neurosurg Psychiatry 2014; 85:220-6.
5. International Paralympic Committee. Athletics Classification Rules and Regulations. www.paralympic.org 2014;
6. Pare?s I, Saifee T, Kassavetis P. Believing is perceiving: mismatch between self-report and actigraphy in psychogenic tremor. Brain 2012; 135:117-23.
7. Wrench J, Wilson SJ, Bladin PF. Mood Disturbance before and after Seizure Surgery: A Comparison of Temporal and Extratemporal Resections. Epilepsia 2004; 45:534-43.
Conflict of Interest:
HIV and lower risk of multiple sclerosis: protective or subjugating effect?
Dear Sirs, Gold and colleagues recently found a significantly decreased risk of developing multiple sclerosis (MS) after the onset of HIV infection in a large cohort of national linked data set of English Hospital Episode Statistics.(1) The possible causes of this negative association have been hypothesized to be immunodeficiency and antiretroviral treatment (ART) as MS is usually treated with immunosuppressive drugs and its pathogenesis has been linked to human endogenous retroviruses. Since the ART might improve HIV-related immunodeficiency being these two variables inversely correlated, and reliable data on the ART could not be deduced with certainty from the database of the study, this supposition leaves some doubts. With this letter we want to discuss the supposed protective mechanism of HIV against MS. HIV is an immunodeficiency syndrome with progressive CD4+ T lymphocyte loss leading to the development of opportunistic infections, cancers and death especially in untreated patients. However, also autoimmune diseases with rheumatological, haematological, endocrinological and neurological manifestations have been already described in the early pre-ART era.(2) Similarly to what was observed for MS,(1) clinical and serological improvement of systemic lupus erythematosus during the onset of HIV has been reported in some cases, therefore, a therapeutic effect of HIV on autoimmune diseases was already hypothesized.(2) In the ART age, while several autoimmune diseases have been shown to occur at a lower rate than before in HIV patients, other ones (e.g. sarcoidosis) have contrariwise a higher incidence.(2) Furthermore, some autoimmune manifestations may occur contemporarily with the immune reconstitution inflammatory syndrome (IRIS) associated with ART, making particularly difficult their diagnosis.(2) Therefore, the hypothetical protective effect of HIV against MS could be explained in part by a possibility of misdiagnosis of the latter, as acknowledged by the authors themselves.(1) In effect, the authors excluded from the analysis of the HIV cohort five people with prior MS and three people with a simultaneous record of HIV and MS, whereas they included 7 new observed cases during the median follow-up period of 2454 days after the diagnosis of HIV. Indeed, HIV infection might manifest with MS-like clinical and radiological features and with presence of oligoclonal bands in cerebrospinal fluid (CSF), as well as severe inflammatory demyelinating lesions have been observed during IRIS after the onset of ART. Since the diagnostic criteria of MS recommend the exclusion of other pathologies, it is logical to assume that after being diagnosed with HIV the new neurological manifestations are more readily attributed to the latter omitting the diagnosis of MS. In our opinion, the effect of HIV on MS is more correct to be defined as subjugating rather than protective. However, we agree with the authors that by studying the relationships between these two diseases we can better understand the pathogenesis of MS due to its immunological similarities with HIV. Even if for a long time the role of CD4+ and CD8+ T lymphocytes has been emphasized in both MS and HIV, more recently a dysregulation of the innate immunity has been extensively demonstrated in HIV, MS and other autoimmune disorders.(3,4) In particular the natural killer (NK) cells have been demonstrated to be implicated in these pathologies influencing the activity of other components of the innate and adaptive immune systems.(5) NK cells foster anti-viral and anti-tumour immunity recognizing and killing virally-infected or neoplastic cells. A small RNA HIV-1 virus has developed specific strategies to evade control of the NK cells.(3) A functional impairment of NK cell response and in particular their decreased cytotoxic activity has been shown since the early phases of HIV infection persisting during disease progression.(3) HIV-infected individuals have shown progressive expansion of functionally anergic NK cell subset, thus it has been hypothesized that these subjects have an incomplete activation of NK cells due to chronic stimulation leading to NK cell exhaustion and anergy.(3) These anergic NK cells, accumulated during progressive HIV-1 infection, have not produced IFNgamma and TNFalpha by a stimulation with MHC-devoid target cells, reducing a consequent activation of antigen-presenting dendritic cells and components of adaptive immunity.(3) Interestingly, NK cells show similar alterations in both HIV infection and autoimmune diseases, even if the latter are not generally considered as infectious disorders.(4) Several studies have reported both a decreased number of peripheral blood NK cells and an impairment of their cytotoxicity in patients with different autoimmune diseases.(4) However, more recent works have demonstrated accumulation of NK cells in target tissues of several autoimmune diseases such as in pancreatic islets in type I diabetes mellitus, hair follicles in alopecia areata, muscles in juvenile dermatomyositis and synovia in rheumatoid arthritis, supporting the possibility that a decrease of circulating NK cells in autoimmune disorders is consequent to their trafficking to the affected tissues.(4) The functional impairment of NK cells was found prevalently in the early phase of autoimmune diseases and, even at the time of their diagnosis it appears more likely that the NK defect is primary and not secondary to the disease progression or to the treatments.(4) Moreover, the NK dysfunction is present in active but not in quiescent phase, suggesting that NK cells may be involved particularly in the initiation of the disease process.(4) Finally, the same killer immunoglobulin-like receptor/HLA associations fostering NK activation protect against the infections and predispose to autoimmune diseases including MS.(4) In MS, the NK cells might lyse directly oligodendrocytes, astrocytes, microglia and activated T cells, thus having a probable immunoregulatory role.(4) Moreover, transitory reductions of NK cytolytic activity, called "valleys", have been demonstrated to precede radiological and clinical relapses whereas the CD56bright NK cells, more efficient cytokine and chemokine producers compared to the potent cytolytic CD56dim effectors, have been shown a substantial enrichment in the CSF.(4) Finally, NK cells show close modifications also during viral infections, being their number and their cytotoxicity reduced in the peripheral blood with a shift from CD56dim to CD56bright cells.(5) Taken together, these features support the hypothesis that MS as well as other autoimmune diseases may be an expression of latent, chronic infections due to an inadequate immune response to pathogens. Such immune reaction weakens further in HIV infection up to be completely subjugated in the most severe HIV stages. References 1. Gold J, Goldacre R, Maruszak H, Giovannoni G, Yeates D, Goldacre M. HIV and lower risk of multiple sclerosis: beginning to unravel a mystery using a record-linked database study. J Neurol Neurosurg Psychiatry. 2015 Jan;86(1):9-12. doi:10.1136/jnnp-2014-307932. 2. Stratton R, Slapak G, Mahungu T, Kinloch-de Loes S. Autoimmunity and HIV. Curr Opin Infect Dis. 2009 Feb;22(1):49-56. doi: 10.1097/QCO.0b013e3283210006. 3. Altfeld M, Fadda L, Frleta D, Bhardwaj N. DCs and NK cells: critical effectors in the immune response to HIV-1. Nat Rev Immunol. 2011 Mar;11(3):176-86. doi: 10.1038/nri2935. 4. Fogel LA, Yokoyama WM, French AR. Natural killer cells in human autoimmune disorders. Arthritis Res Ther. 2013 Jul 11;15(4):216. doi: 10.1186/ar4232. 5. Mandal A, Viswanathan C. Natural killer cells: In health and disease. Hematol Oncol Stem Cell Ther. 2014 Dec 27. pii: S1658-3876(14)00108-3. doi:10.1016/j.hemonc.2014.11.006.
Conflict of Interest:
The strange case of bilirubin in Parkinson's disease
Hatano and colleagues recently published a paper of considerable interest, investigating possible metabolic pathways associated with Parkinson's disease (PD) by using metabolomic technologies . Their results on redox homeostasis deserve to be further discussed, since oxidative stress is possibly involved in PD risk and progression. In particular, authors found bilirubin, a strong natural antioxidant, to be significantly reduced in patients with PD, as compared to controls . However, there are different studies reporting conflicting results on bilirubin metabolism in PD. From a pathophysiological perspective, the production of bilirubin and, subsequently, its plasma levels are mainly related to heme-oxigenase (HO) activity [2-3]. The up-regulation of the HO-bilirubin pathway is an early response to oxidative stress within dopaminergic cells and, accordingly, cytoplasmatic Lewy bodies of PD patients display intense peripheral HO staining . In line with this, Scigliano and colleagues previously reported increased total bilirubin levels in PD , and, similarly, we recently confirmed this result in our population of newly-diagnosed, drug- na?ve PD subjects . These findings are supported by the hypothesis that HO up-regulation within the substantia nigra is an adaptive response to increased oxidative stress, occurring since the early phases of PD, and is subsequently responsible for systemic bilirubin increase [2-3]. On the other hand, Hatano and colleagues reported reduced bilirubin levels in PD, compared to controls, possibly as a consequence of increased oxidative stress , whereas Qin and colleagues found no difference in total bilirubin concentrations between PD cases and controls . These discordant results can be explained by the presence of confounding factors affecting bilirubin levels and/or by bilirubin variations during the course of the disease. Among possible confounding factors, for instance, we must report the presence of HO polymorphisms, which probably modify bilirubin levels in PD cohorts with different genetic background . There are also several comorbidities affecting bilirubin that are difficult to exclude completely in clinical practice, in particular for studies with small sample size . Finally, it is possible to hypothesize a variability of bilirubin levels during the course of PD. Considering different studies that have been conducted so far, it can be hypothesized an increase in bilirubin levels in the early phases of PD, with subsequent gradual decrease during the course of the disease, due to progressive reduction of the antioxidant reserve [1,4-5]. However, since bilirubin increase is generally considered a marker of improved health outcomes in the general population [2-3], PD patients presenting higher bilirubin levels in both early and late phases of PD are conceivably those with better response to the increased oxidative stress and, thus, are expected to have better motor performances, as described by Hirano and colleagues, and in our population [1,5]. As a future perspective, considering that all previous studies presented a cross-sectional design [1,4-6], further investigations should be conducted with a longitudinal design in order to specifically investigate the modifications of bilirubin levels during the course of the disease in relation to dopaminergic treatments, disease progression and/or PD-related pathological changes [2-3]. In conclusion, the HO-bilirubin pathway seems to be affected by various factors and, thus, appears a dynamic antioxidant mechanism with a significant role in PD. In particular, we thank Hatano and colleagues for their contribution in this field, and strongly encourage further studies investigating variations in bilirubin levels during the course of PD with subsequent health outcomes.
References 1. Hatano T, Saiki S, Okusumi A, et al. Identification of novel biomarkers for Parkinson's disease by metabolomic technologies. J Neurol Neurosurg Psychiatry 2015. 2. Schipper HM, Song W, Zukor H, et al. Heme oxygenase-1 and neurodegeneration: expanding frontiers of engagement. J Neurochem 2009;110(2):469-485. 3. McCarty MF. Serum bilirubin may serve as a marker for increased heme oxygenase activity and inducibility in tissues - A rationale for the versatile health protection associated with elevated plasma bilirubin. Med Hypotheses 2013;81(4):607-610. 4. Scigliano G, Girotti F, Soliveri P, et al. Increased plasma bilirubin in Parkinson patients on L-dopa: evidence against the free radical hypothesis? Ital J Neurol Sci 1997;18(2), 69-72.? 5. Moccia M, Picillo M, Erro R, et al. Increased bilirubin levels in de novo Parkinson's disease. Eur J Neurol 2015. 6. Qin XL, Zhang QS, Sun L, et al. Lower Serum Bilirubin and Uric Acid Concentrations in Patients with Parkinson's Disease in China. Cell Biochem Biophys 2014. 7. Ayuso P, Mart?nez C, Pastor P, et al. An association study between Heme oxygenase-1 genetic variants and Parkinson's disease. Front Cell Neurosci 2014;8:298.
Conflict of Interest:
Role of advanced MR techniques such as Diffusion Tensor Imaging in Leber's hereditary optic neuropathy and Multiple Sclerosis
As a research intern aspiring to be a neurologist, I found Dr. Mathew et al. article highly interesting and thought provoking . Multiple sclerosis is a complex neurological condition to manage, given its numerous phenotypes.
It was very interesting to note that the authors found similar imaging features on conventional MR brain scan in patients with multiple sclerosis (MS)-like disease in association with LHON (LMS) as well as multiple sclerosis (MS) and hypothesized that mitochondrial dysfunction could be a common pathophysiological pathway in the formation of white matter lesions in these disorders .
Diffusion tensor MR imaging (DT MRI) has shown to be useful in detecting micro-structural alterations in white matter and grey matter in MS, in seemingly "normal -appearing white matter and gray matter" on conventional MR images [2,3]. Recent studies also indicate that DT MRI may demonstrate characteristic features in LHON such as decreased fractional anisotropy (FA) and an increased mean diffusivity and radial diffusivity, affecting exclusively the optic tracts and optic radiations, and in some patients the acoustic radiations [4,5]. In that regard, it would be useful to know if DT MRI could further identify any specific micro- structural alteration that are common in these two conditions, which may indeed act as a biomarker, and perhaps fuel future research in genotype- phenotype correlation utilizing advanced MRI techniques including DT MRI and functional MRI techniques.
References 1. Matthews L, Enzinger C, Fazekas F et al. MRI in Leber's hereditary optic neuropathy: the relationship to multiple sclerosis. J Neurol Neurosurg Psychiatry. 2015 May; 86(5):537-42
2. Fox RJ. Picturing multiple sclerosis: conventional and diffusion tensor imaging. Semin Neurol. 2008 Sep; 28(4):453-66
3. Goldberg-Zimring D, Mewes AU, Maddah M, Warfield SK. Diffusion tensor magnetic resonance imaging in multiple sclerosis. J Neuroimaging. 2005;15(4 Suppl):68S-81S.
4. Milesi J, Rocca MA, Bianchi-Marzoli S et al. Patterns of white matter diffusivity abnormalities in Leber's hereditary optic neuropathy: a tract-based spatial statistics study. J Neurol. 2012 Sep; 259(9):1801-7
5. Manners DN, Rizzo G, La Morgia C et al. Diffusion Tensor Imaging Mapping of Brain White Matter Pathology in Mitochondrial Optic Neuropathies. AJNR Am J Neuroradiol. 2015 Mar 19.
Conflict of Interest:
Re:New Insights on AD: Comment on The identification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis
Thank you for your enthusiasm for our study, and for your questions.
In our opinion, an extensive neuropsychological test battery is mandatory for diagnosis of probable AD dementia. An MMSE score alone is not sufficient for the assessment of cognitive impairment.
We used MMSE as indicator for disease severity, within our sample of already diagnosed probable AD patients. It is an interesting suggestion to use the MoCA for this purpose, because this test focuses more on several non-memory domains. However, we preferred MMSE because it is commonly used and easy to interpret.
Mean age of the patients in our cohort was 69+/-9 years old (shown in table 1). Mean ages per cluster are given in table 4.
Conflict of Interest:
Visit the full archive of podcasts for JNNP here >>
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JNNP.
View free sample issue >>
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.